New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:40 EDTGEVASynageva BioPharma announces 6 month data from extension study of SBC-102
Synageva BioPharma announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase, LAL, Deficiency at the American Association for the Study of Liver Diseases, AASLD, annual meeting being held in Boston, MA, November 9-13.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
16:32 EDTGEVASynageva reports sebelipase alfa data at NASPGHAN meeting
Subscribe for More Information
October 21, 2014
16:19 EDTGEVASynageva announces submission of BLA to the FDA for sebelipase
Synageva BioPharma announced the start of a rolling submission of a Biologics License Application, or BLA, to the FDA for sebelipase alfa as a treatment for patients with lysosomal acid lipase deficiency, a rare genetic disease with significant morbidity and early mortality. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company anticipates completing the rolling submission of the BLA to the FDA and submitting the Marketing Authorization Application to the European Medicines Agency) by the end of January 2015.
09:48 EDTGEVAShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
October 16, 2014
10:01 EDTGEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:53 EDTGEVASynageva initiated with a Buy at SunTrust
Target $117.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use